Efsinvestment.com website offers simple do-it-yourself type of investment ideas. You can download excel files that can easily calculate the Fair Value of a stock, along with O-Metrix score and Margin of Safety.
Investment philosophy is to first determine the maximum loss, and invest accordingly. Like many value investors, we prefer to invest in stocks with the highest dividend yields, and highest EPS growth potentials. Telecommunication and energy stocks in emerging markets are among the favorites.
Seeking Alpha offers a great opportunity to become a part of a strong finance network. Based on extensive quantitative analysis, in any market, going short is risky. Statistical analysis shows that technical indicators work only if they are strong enough to convince the majority of the investors. Do not buy a stock at the top, do not sell a stock at the dip.
Mr. Rosenman has nearly 15-years executive experience in the health and wellness sectors, including weight loss, cosmetics skincare and nutrition, both Rx and OTC. Expertise areas include strategic market and product planning and corporate development (evaluation, recommendation and execution of strategic alliances and acquisitions). A MBA graduate of the Sweigart School of Business at Rider University, Rosenman devotes a portion of time back to the collegiate community as a graduate-level adjunct professor for healthcare marketing, consumer behavior and strategic planning. He has several published works in the field of U.S health and wellness, including a focus on how nutritional ingredients will transition into Rx space, specifically with lipid and herbal managment. His current professional role is with one of the fastest growing nutritional companies in the U.S., which also produces Rx and OTC products. He has served as an advisory board member to various organizations in the healthcare field, from venture start-ups to top global enterprises. Mr. Rosenman is a Senior Advisor with Guidepoint Global and is called upon by large institutional investors for insight and expert opinion on healthcare market opportunities (to date he has advised on more than $2 billion USD of related transactions/funding).
EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
David Zanoni is ranked in the top 1% of blogging analysts on Tipranks.com for performance and accuracy. He focuses on growth & momentum stocks that are reasonably priced and likely to outperform the market over the long-term. David is a graduate of Rutgers University with a B.S. in Management. He is an independent long term investor of quality stocks and uses options for strategy. David believes in the power of innovation, capitalism, and the characteristics of the American spirit: intellect, fortitude, and adaptability to lead our country and the world to growing prosperity. His wants to help make people money by investing in high-quality growth stocks.
I am a mid-westerner and computer science grad helping to launch a start-up medical service company. I've worked on medical intake including XML delivery, medical instrumentation imaging, tissue ablation micro-imaging and MEMs device modeling.
I know biotech, which I prefer to call biopharmaceuticals. Period. I love investing and I write when I can!
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
Our small-cap hedge fund strategy beat the market by 44 percentage points since its inception 18 months ago. Visit our website to learn how you can do the same. Insider Monkey is a finance website that provides free hedge fund and insider trading data. We believe ordinary investors can beat the market by imitating insiders and best hedge fund managers. They have access to better information and experts than ordinary investors do. Take advantage of the SEC filings where hedge funds and insiders disclose their stock transactions.
Here is our team:
Ms. Krishnamsetty is the Editor of Insider Monkey. Prior to creating Insider Monkey with Dr. Dogan, Ms. Krishnamsetty was Associate Producer at Bloomberg Television. Prior to that, Ms. Krishnamsetty was on the afternoon news team at CNBC. Additionally, Ms. Krishnamsetty reported for NPR and worked as a risk management consultant at Marsh & McLennan. Ms. Krishnamsetty has a M.S. in Journalism from Columbia University’s Graduate School of Journalism.
Insider Monkey’s hybrid evaluation system ...More was created in 2003 by Dr. Ian Dogan. Dr. Dogan has a Ph.D. in financial economics with a specialization in insider trading. Dr. Dogan has provided consulting services to institutional investors and hedge funds, and managed a $200+ million fund using a strategy he developed utilizing insider transactions. Dr. Dogan recently authored the insider trading chapter of soon to be published “The Handbook of Investment Anomalies” by Zacks Investment Research. Insider Monkey will serve the outcome of the methodologies developed by Dr. Dogan to ordinary investors who don’t have access to academic quality research and tools to shape their investments.
For your inquiries please contact us at email@example.com
Vineet Dutta currently holds a Masters in economics and is currently works as a consultant in the risk management space. Before working as a consultant he has worked at one of the large money center banks, where he worked within the institutional counterparty risk organizations. Vineet’s has been actively involved in the capital market space for ten years. His investment theories are based around macro economic trends globally as well using option strategies to help maximize returns and minimize losses.
At Bio Vantage, our mission is to provide high-quality equity reports focused primarily on biotech and pharmaceutical companies worldwide. In our view, fundamental analysis of biopharmaceutical companies requires expertise in evaluating clinical trial data and drug pipelines, as these events often drive the underlying equity value of such companies going forward. Equally important is the ability to forecast future revenues, earnings growth, and cash flows using financial modeling tools in order to derive an intrinsic value for the company being analyzed. Once a fundamental value is derived, investors can make profits from a variety of trading instruments.
While our expertise largely concerns biotech and pharmaceutical companies, our investment principles are centered on diversification, asset allocation, risk management, and portfolio strategies. Thus, our investments and analyses also cover other sectors, including technology, financials, consumer products, energy, and commodities.
Bio Vantage's analysts have extensive experience in the biomedical field and in drug discovery research. We are lifelong investors. One of the analysts holds the CFA charter designation.
Peter Geschek is a freelance writer, investor and the publisher of www.medfrontiers.com website. This is a site for medical innovation news and clinical trials news. Short, concise, important information about the latest is biotech and pharmaceuticals.
I focus on investments in the oil & gas & MLP sectors with an eye for dividend income growth and long-term capital appreciation. I typically allocate a portion of my own portfolio and devote some of my Seeking Alpha articles to small and medium sized companies offering compelling risk/reward propositions. I am an engineer, not a qualified investment advisor. While the information and data presented in my articles are obtained from company documents and/or sources believed to be reliable, they have not been independently verified. Therefore, I cannot guarantee its accuracy. I advise investors conduct their own research and/or consult a qualified investment advisor. I explicitly disclaim any liability that may arise from investment decisions you make based on my articles. Thanks for reading and I wish you much success with your investments.
Andrew McDonald is a healthcare investment professional with expertise in identifying transformative medicines as well as in forecasting clinical trial, regulatory, and sales outcomes. Prior to co-founding LifeSci Advisors, Andrew most recently served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004-2006, Andrew was Co-head of Healthcare Research and Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001-2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal chemist at Pfizer from 2000-2001. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.
I have been analyzing and trading stocks for over 10 years. I have primarily studied and followed value investors like Warren Buffet. However, I also believe that technical analysis can play a role in analyzing a stock before making an investment. I have found that solid financial analysis, combined with the ability to understand current market psychology is key to investment success.
I also find the best trading spot is far away from Wall Street, my favorite place is a sunny beach in Mexico.
I am planning to form a small private equity company which will focus on activist investing and possibly buyouts of smaller capitalization companies.
I am an individual investor. I am here to share the information on Stocks - Biotechnology, Information Technology, Consumer, Retail, Finance, Energy and wherever we can make money ;-)
Zacks.com brings the decades of study and stock picking expertise of Zacks Investment Research to individual investors. Now, you don't to be an investment bank or brokerage firm to get the professional power of Zacks' research. It's all available on Zacks.com. Learn more about Zacks' history and company below.
Tim Travis is a veteran deep value investor and money manager. Travis has extensive experience in traditional investments such as stocks and bonds, in addition to having a unique methodology of combining options and distressed investing with value investing to generate income, reduce risk, and to add an element of timing. Currently Tim Travis is the founder, Chief Executive Officer, and Chief Investment Officer of T&T Capital Management. T&T Capital Management is an Irvine, California based Registered Investment Advisor that manages accounts for both individual and institutional investors.
Travis was born in Laguna Beach, California and became captivated with the value investment philosophy in his early teens through reading books written by Benjamin Graham, and the shareholder letters from Berkshire Hathaway, and the Buffett Partnership L.P. Tim Travis became intrigued by the notion that stocks aren’t just pieces of paper but instead are fractional shares of a business that can be analyzed by comprehensive analysis of the balance sheet, income statement, and statement of cash flows. He majored in Business and Economics at the University of California Santa Barbara, graduating in 2004, and he also had the privilege of studying international economics at the University of Richmond in Florence, Italy. Tim Travis got his feet wet in finance working for both Scottrade and AG Edwards & Sons during his college career. Upon graduation Travis worked at the Vanguard Group in Scottsdale, Arizona. It was there that he learned that most mutual funds underperform their respective indexes, and he became disappointed at the overwhelming diversification in most mutual funds, that really makes most of them function as “closet” index funds.
After leaving the Vanguard Group, Travis worked for a small futures and commodities firm in Mission Viejo, California. It was there that Tim developed an adept knowledge of options, particularly the selling of options to take advantage of the higher probabilities involved. It was also during this time in his life that Travis began reading everything he could possibly find on value investing. Some of his role models in the field are Warren Buffett, Martin Whitman, Bruce Berkowitz, Seth Klarman, Peter Lynch, Glenn Greenberg, etc. After working with clients from around the world Travis broke away and started T&T Investment Management L.L.C.
At T&T, Travis refined his unique methodology combining value investing, with the selling of options to generate income and reduce risk. T&T experienced explosive growth by partnering with a local commodities firm. After several years Tim Travis realized that without controlling the majority of the company any longer, he didn’t have full control over the company’s strategic direction. Divergent business principles caused Tim Travis to break away and form T&T Capital Management. At TTCM which Tim Travis is the sole owner, he is allowed to offer only the best products and services, at a reasonable price, without conflicts of interest.
T&T Capital Management’s goal is build wealth for both individual and institutional investors, and to accomplish these goals Travis as Chief Investment Officer employs his deep value investing techniques. Each account is managed on a day to day, personal basis, and there are no cookie cutter portfolios defined only by one’s age and risk tolerance. Every security is researched and hand selected by Travis and his research team. T&T Capital Management takes pride in first class customer service and research which is regularly communicated to clients for education purposes.
Peter Way Associates is the only known provider of the price range forecasts of widely-held, actively traded stocks derived from the hedging activities of market-making [MM] firms as they balance big-$-fund sellers and buyers in large block trades. The price ranges offer explicit downside exposure forecasts not commonly found in publicly published investment analyses.
This is all forward-looking data, based on what the MMs will pay for protection against coming unwanted price change while temporarily committed firm capital is exposed to market risks. It is available by modest subscription cost at blockdesk.com.
The behavioral analysis involved has been performed daily since Y2K, now on over 3,000 stocks, ETFs, and market indexes. That has built an actuarial history of how market prices have subsequently behaved following several million price range forecasts, issue by issue.
That data provides a qualitative backdrop to current forecasts in terms of odds of profitable positions, size of prospective gains, credibility of forecasts, and worst-case price drawdown exposure experiences.
Peter F. Way is a veteran Chartered Financial Analyst, having taken and passed the CFA Institute’s required 3 examinations in the first years they were given, 40+ years ago.
Armed with BS in Economics from the Wharton School and an MBA degree from Harvard Business School, he has managed staffs of dozens of Investment Researchers and Quantitative Analysts for the nation’s largest bank, arbitraged index options for NYSE Specialists, and managed portfolios of hundred-million-dollar equity investments for Fortune 100 corporate pension funds and non-profit endowments.
He has been elected President of professional Investment Analyst Societies in San Diego and New York City and has served on the editorial boards of the Financial Analysts Journal and the CFA Digest. He has spoken at numerous schools and professional meetings.
Efficient Alpha provides written content & investment research solutions for small and medium-sized advisor firms. Our core products include: financial newsletters, blogging, presentation preparation, investment research and ghost writing. Our normal clientele are small to medium-sized firms with research, analysis, or marketing needs but whom may have insufficient staff or topic expertise.
Joseph Hogue, founder and analyst, has more than ten years in the investment industry and holds the Chartered Financial Analyst designation. His experience covers a wide range of investment related areas but he specializes in web & social media content for financial advisors and other professionals. His work has been published by the International Economic Development Council, Alternative Latin Investor, Emerging Money, Morningstar, and the financial website Seeking Alpha. Mr. Hogue is also the administrator for the FinQuiz Blog, an online source for CFA exam preparation advice and preparation.
Working from Medellin, Colombia, he has worked for clients ranging from individual investors to large multinational firms. Prior to his work as a financial writer, Mr. Hogue worked as an economist for the State of Iowa, as a consultant on trade issues and analyzed real estate development deals in Colombia.
A veteran of the United States Marine Corps, Mr. Hogue is a graduate of Iowa State University with a B.S. in Finance, a B.A. in Communications, and a Master’s in Business Administration. He is the former Communications Chair on the board of directors for the CFA Society of Iowa.
Areas of Interest:
· Financial Blogging and Social Media Content
· Equity Research and Analysis
· Strategic Asset Allocation & Portfolio Planning
Kapitall is the online finance platform for the next generation, where investing is as easy as drag, drop and trade. With an intuitive and playful user experience, Kapitall offers tools that make it easy to build virtual and real brokerage portfolios, share ideas and research stocks and funds.
Founder of Old School Value (www.oldschoolvalue.com).
Fundamental Stock Analyzer & Valuation Tool for Value Investors to Save Time & Make Money
- Are you spending a lot of time manually gathering and inputting data into spreadsheets?
- Are you finding it difficult to keep up to date with fundamental company valuations?
- Do you need a way to quickly check whether a company is worth investigating?
- Do you want to know what a company is worth quickly?
The Old School Value Stock Analysis Software is a fundamental analysis and valuation tool that works for you.
Save hours each day by automatically retrieving and crunching the financials for thousands of companies.
Keep up to date easily and find more opportunities by analyzing companies faster and use the 5 valuation models to cross check whether the stock price is an attractive entry price or time to get out.
Learn more at http://try.oldschoolvalue.com/stock-analyzer/
I am primarily an investor interested in creating passive income streams through dividends. I focus on finding and analyzing dividend paying stocks, MLPs and REITs that are a good fit for income investors.
I practice Judaism and my faith is very important to me. I visit family in Israel once a year, but I am educated and work in the United States where I hold an MBA and a bachelor's in English. I am a patient man, enjoy wine but am not a connoisseur, and I listen more than I speak.
I have been an investor in several stock exchanges around the globe for the last 16 years. My trading philosophy is to be ahead of the curve of demand. I strongly believe that diligence and patience are fundamental to stock market success.
I attained my MBA from the Keio Business School and have worked in the field of international business consulting for the last 12 years. My job has allowed me to travel the world, which gives me great joy, as it combines my two passions, to visit new places and finance.
Todd E. Campbell, President & Founder
Follow my latest updates on Twitter: https://twitter.com/ebcapital
Mr. Campbell has been providing alpha generating independent equity research to professional money managers for nearly 15 years. In 2003, Mr. Campbell founded E.B. Capital Markets, LLC, an independent research firm serving professional money management firms. Mr. Campbell founded Gundalow Advisors, LLC, a State Registered Investment Advisor providing investment management services to institutions and high net worth clients in 2013. Today, some of the largest money management firms in the country trust the proprietary research developed by Mr. Campbell, including the Power 7 methodology featured in Mr. Campbell's book "Your Guide to Better Stock Picks: Tips from an Advisor's Advisor". Prior to founding E.B. Capital Markets, LLC, Mr. Campbell was Vice President and Partner of Alpha Equity Research, an independent equity research firm. At Alpha Equity Research, Mr. Campbell's responsibilities included institutional sales and client services. Mr. Campbell also developed new research and distribution products. Additionally, Mr. Campbell was responsible for Alpha’s individual brokerage business, providing investment services to high net worth families. In the past decade, Mr. Campbell’s articles have been featured in the Market Technician’s Association trade journal and his insights have been featured in various print and online financial publications, including Barron’s & SmartMoney. Mr. Campbell has also appeared on the financial news network, CNN/fn. Mr. Campbell is a graduate of the University of New Hampshire, where he studied English, Psychology and Business Administration with a focus on economics.
I am a small-time writer/blogger who dreams big and enjoys researching and writing about biotechs and pharmaceuticals. My work experiences include food safety, water quality, pesticides, food additives, paints, plastics and pharmaceutical precursors. My focus as of late has been researching the treatment options for many cancers and prevention of their recurrence. Additional recent research has been in the stem cell field, an exciting field in its infancy but now becoming a teenager! My ongoing goal for investors is attempting to find under-the-radar or oversold pharmaceuticals or biotechs for investment potential.
Benjamin Shepherd, editor of Global Investment Strategist (http://www.globalinvestmentstrategist.com), focuses on time-tested investment strategies and high growth emerging markets which have proven themselves in both bull and bear cycles. He and his team spend hours every month discussing the state of the global economy and the markets with many of the best known and well-respected money managers in the industry. They then distill that wisdom and their own analysis into actionable advice geared towards generating returns while preserving capital for equity investors. Mr. Shepherd is also editor of Benjamin Shepherd's Wall Street, formerly Louis Rukeyser's Wall Street, and associate editor of Personal Finance, one of the world’s most widely-read investment newsletters, contributing his knowledge of the fund industry and emerging markets to the newsletter’s ongoing commentary.
A new age platform for the latest in finance and everything else.
Through Bidness Etc, we’re bringing the 99% back in the loop by presenting the best financial research in the simplest and most creative ways possible.
We have distilled a decade and billions of dollars’ worth of trading experience into developing the idea behind Bidness Etc, and we feel we can do a better job of analyzing and reporting financial matters than anyone else.
We are a team of more than 60 financial wizards, musicians, rock stars, artists, singers, aspiring philosophers and tech geeks working hard to change the way human beings think and interact with finance.
We know that quality financial analysis requires a higher level of intelligence, and that what is reported by financial media is too far behind the curve to be of any relevance to the savvy reader. Here’s our solution to that problem: a platform that gives away the best information and analysis out there for free, thereby democratizing individuals’ access to finance. We’re also pushing the envelope by delivering it visually.
We feel that by doing so, Bidness Etc. will become humanity’s first step into a new age for financial media, and that we’ll set the standards for tomorrow with our revolutionary new product.
And that’s not all.
We know that figures, facts, numbers and stats can get quite mind-numbing after a while. Therein lies the kicker: we’re presenting our data in the most visually appealing ways possible. By doing so, we are quite literally transforming financial reporting into a new form of art. We have also incorporated an entertainment section in our website, which tracks the global zeitgeist and provides our take on the hottest topics trending on the web. We feel that this will help us take finance to the mainstream, and complete what the Bidness Etc. experience is all about.
This is a beta version of our web portal. We hope it will keep you coming back for more, because we have a major surprise in store for readers for the month of November. Here’s a spoiler, though: finance will never have looked better once we go all out! And you’ll know we’ve meant Bidness all along when we claim to become the best place on the web.